PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Bromocriptine”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,225 records · Page 68Linked to original sources

Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status.

BACKGROUND: The prognosis of low performance status (PS) patients with advanced non-small-cell-lung cancer (NSCLC) is dismal. In these patients, we have determined the survival, clinical benefits, and toxicity of a multidrug regimen, based on cyclophosphamide and biotherapeutical agents. METHODS: Patients with a diagnosis of stage IIIB or stage IV NSCLC, no previous surgery or chemoradiotherapy, and an Eastern Cooperative Oncology Group (ECOG) PS equal to or greater than 2 received a daily combination of somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide. RESULTS: Twenty-eight (28) patients were enrolled. The median age was 64 years (range, 35-74). The PS was 2 and 3 in 78.6% and 21.4% of patients, respectively. The median overall survival (intent-to-treat analysis) was 12.9 months (range, 1.5-33.5 months), The overall survival rates at 1 and 2 years were 51.2% and 21.1%, respectively. The side-effects were very mild, mostly consisting of diarrhoea, nausea/vomiting, and drowsiness of grade 1-2. Most patients experienced an improvement of both respiratory (cough and dyspnoea) and general (pain, fatigue, and insomnia) symptoms. CONCLUSIONS: Low PS patients with advanced NSCLC may benefit from a combination of somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide, in terms of survival and quality of life, with very low side-effects.

Adult↗

A new approach combining interferon and bromocriptine LA to prevent spontaneous mouse mammary carcinoma.

The development of spontaneous mammary carcinoma in C3H mice is mainly attributed to an oncogenic virus (MMTV) and the high prolactin levels of this inbred strain. Interferon (IFN) reduces the incidence of mammary carcinoma in virgin C3H mice when administered during lactation. Bromocriptine LA, an antiprolactin drug, also decreases the incidence of this tumor in C3H mice. The combined action of mouse IFN-alpha + beta and bromocriptine LA had a significant anticarcinogenic effect more significant than either of the above agents administered independently. This antitumor action was effective in virgin C3H mice only.

Animals↗

Hypotensive effect of bromocriptine in normal eyes.

The effect of a single oral dose of 2.5 mg Bromocriptine on intraocular pressure over a 12 hour period in a group of 20 puerperal women with normal eyes, is reported. Intraocular pressure was significantly reduced, the maximal response being 3-4 hours after administration. Possible explanations for the reducing effect of Bromocriptine on intraocular pressure are discussed.

Administration, Oral↗

Hypotensive effect of bromocriptine in glaucomatous eyes.

The effect of a single oral dose of 2.5 mg bromocriptine on intraocular pressure in 20 glaucoma patients is reported. Intraocular pressure was significantly reduced (31%), the maximal response being after 4-6 hours. A decrease in blood pressure was also noticed, maximal reduction (5%) at 4 hours. Three patients experienced nausea and dizziness. Possibly the reducing effect of bromocriptine on intraocular pressure is mediated by the stimulation of intraocular dopamine receptors (DA2).

Administration, Oral↗

Effects of dopamine agonist, bromocriptine, and some dopamine antagonists on ocular blood flow.

A dopamine agonist, bromocriptine, and several dopamine antagonists, domperidone, haloperidol, floropipamide and chlofluperol, were studied for their effects on the ocular blood flow. Both domperidone and haloperidol are ocular hypotensive agents and are able to increase the ocular blood flow significantly. Floropipamide had little effect on the intraocular pressure (IOP), yet it reduced the ocular blood flow markedly. Chlofluperol is an ocular hypertensive agent, yet it increased the ocular blood flow significantly. Although bromocriptine lowered the IOP, it did not affect the ocular blood flow. These results indicate that the changes of ocular blood flow are independent of the changes of the IOP. Therefore, it is critical to develop antiglaucoma agents which can increase retinal and choroidal blood flow in addition to lowering the IOP.

Animals↗

Resumption of pituitary and ovarian activity post-partum: endocrine and ultrasonic observations in bromocriptine-treated women.

The resumption of pituitary and ovarian activity was investigated by hormonal measurements and ultrasound scanning in 45 healthy post-partum women who were treated with bromocriptine. Bromocriptine, 50 mg (Parlodel LAR) was administered within 24 h post-partum. Plasma luteinizing hormone, follicle stimulating hormone, oestradiol, progesterone and prolactin concentrations were measured repeatedly and correlated with ultrasound measurements. Forty-one of the 45 women completed the study. A prompt fall in prolactin levels to normal (non-pregnant) values was observed within 24 h post-partum. Hereafter, a rapid return of the normal menstrual cycle was observed. Endocrine evidence of ovulation was obtained in 19/41 women within 1 month post-partum. Ultrasound measurements started at day 10 and were repeated regularly in 40 women. Ultrasound evidence of ovulation was found in 25/40 women. Ultrasound findings appeared not to correspond with the hormonal measurements. It is concluded that the resumption of pituitary and ovarian secretory functions post-partum is not always paralleled by a concomitant recovery of normal follicular growth and ovulation. Application of a progesterone threshold to judge resumption of ovulation post-partum should be reconsidered.

Adolescent↗

Relief of sleep apnea in acromegaly by bromocriptine.

A patient with longstanding acromegaly complicated by sleep apnea was treated with bromocriptine prior to surgery. In addition to a significant reduction of the plasma growth hormone concentration and measurable decrease in acral overgrowth, a dramatic improvement of the sleep apnea was observed. After three months of therapy, the amount of sleep time occupied by apneic episodes fell from 48 to 12%. The response indicates: (a) that the sequelae sleep apnea in acromegaly can be improved even when ablative therapy of the pituitary is impossible and (b) bromocriptine may prevent perioperative complications caused by clinically significant airway obstruction in patients with acromegaly.

Acromegaly↗

Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine.

To determine the mechanisms by which calcium channel blockade with verapamil causes hyperprolactinemia, the authors investigated the effects of this blockade on the prolactin (PRL) responses to stimulation by thyrotropin releasing hormone (TRH) and inhibition by dopamine, using L-dopa and bromocriptine. Verapamil, given for 1 week at a dosage of 240 mg orally to eight healthy volunteers, induced a significant elevation of basal PRL levels (17.3 +/- 1.8 ng/ml to 30.9 +/- 4.3 ng/ml, p < 0.005). Verapamil also caused an increase in the PRL response to a TRH (100 micrograms). However, when the increased basal level was considered by calculating the area under the THR response curve and subtracting the basal values, this increase (1763.4 +/- 202.6 ng/ml.min to 2260.6 +/- 223.9 ng/ml.min) was not found to be statistically significant (p > 0.05). Verapamil had no effect on the basal or TRH-stimulated thyroid stimulating hormone levels. In these same volunteers, PRL levels decreased from 13.2 +/- 2.5 ng/ml to a nadir of 5.5 +/- 1.6 ng/ml in response to L-dopa. After 1 week of verapamil 240 mg, basal PRL levels were elevated to 21.5 +/- 3.1 ng/ml, then decreased to 8.2 +/- 1.8 ng/ml with L-dopa. The percentage decreased in PRL in response to L-dopa (60 +/- 5% versus 62 +/- 3%) were not significantly different (p > 0.05). Verapamil had no effect on the basal or L-dopa-stimulated growth hormone levels. Bromocriptine 2.5 mg given to five volunteers twice daily caused PRL levels to fall from 13.3 +/- 1.6 ng/ml to 5.0 +/- 0.9 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Effects of bromocriptine on human subjects depend on working memory capacity.

Pharmacological manipulation of brain dopamine concentration affects visuospatial working memory in humans and in animals, the latter effects localized to the prefrontal cortex. However, the effects of dopamine agonists on humans are poorly understood. We hypothesized that bromocriptine would have an effect on cognitive functions associated with the prefrontal cortex via its effects on cortical dopamine receptors and on subcortical receptors in areas that project to the neocortex. We found that the effect of bromocriptine on young normal subjects depended on the subjects' working memory capacity. High-capacity subjects performed more poorly on the drug, while low-capacity subjects improved. These results demonstrate an empirical link between a dopamine-mediated working memory system and higher cognitive function in humans.

Association Learning↗

Age-related effects of bromocriptine on sensory gating in rhesus monkeys.

Declines in dopamine neurotransmission are a robust characteristic of the process of normal aging. Using neuroimaging, biochemical and cognitive methods, age-related reduction of D2 receptor has been noted in a wide range of species. On the other hand, it is well known that dopamine plays a crucial role in the modulation of sensory gating. Here, we examined age-related alterations of D2 receptor in rhesus monkeys, using a sensory gating paradigm. The direct D2 receptor agonist, bromocriptine, was characterized in young adult and aged monkeys. We found bromocriptine disrupted sensory gating in young adult monkeys but not in aged ones. Our results provided new evidence that there is a functional decline of D2 receptor in aged monkeys.

Aging↗

Bromocriptine treatment for perseveration in demented patients.

Some forms of behavioral perseveration may reflect the disruption of specific neurotransmitter systems including mesencephalic dopaminergic projection. We present an open-labeled trial of a dopamine agonist for treating perseveration in dementia. Eight patients with ischemic vascular or degenerative dementia completed a 25-day trial of bromocriptine with a maximum daily dose of 10 mg. Patients were assessed with neuropsychological scales and a test battery for detecting perseveration. Recurrent and stuck-in-set types of perseveration significantly improved during the treatment, whereas measures for general attention and overall cognitive function showed no significant changes. We assume that bromocriptine supplemented the mesolimbocortical or ventral mesostriatal dopamine system ameliorated a certain frontal lobe function such as focused attention or working memory and improved the patients' perseverations. Although this study is preliminary because of the small sample size and open-labeled design, the results underline the possibility of pharmacotherapy for perseveration and recommend a double-blind, placebo-controlled study.

Aged↗

Prolactin response to bromocriptine in flunarizine-treated migrainous women.

Flunarizine, a calcium channel blocker, is widely used in migraine prophylaxis. Although an antidopaminergic effect has been suggested for this drug, it is unclear whether the antimigraine action of flunarizine involves the dopaminergic system. We studied the inhibitory response of prolactin to acute administration of bromocriptine, a D2 dopamine receptor agonist, before and after 1 month of treatment with flunarizine in migrainous women. Flunarizine treatment increased basal prolactin levels, but it did not reduce the inhibitory response of prolactin to acute bromocriptine administration. These findings do not support the hypothesis that flunarizine acts as a direct antagonist at the D2 dopamine receptor.

Adult↗

Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study.

Four patients with prolactin-secreting pituitary adenomas were examined with positron emission tomography using L-[11C]methionine to monitor the effect of dopamine agonist treatment on the amino acid metabolism in the tumors. Within the first few hours after intramuscular injection of bromocriptine retard (50 mg) the amino acid metabolism decreased by 40%. Two of the patients were reexamined 7 and 9 days later and showed a 70% reduction in the metabolism of the adenomas. This metabolic effect was later accompanied by significant tumor shrinkage in all adenomas. It is suggested that bromocriptine has a general and rapid effect on the protein synthesis of the prolactin-secreting pituitary adenoma cells.

Adenoma↗

Bromocriptine mesylate (Parlodel) in the management of amenorrhea/galactorrhea associated with hyperprolactinemia.

The efficacy and safety of bromocriptine mesylate (5 to 7.5 mg per day for up to 24 weeks) were studied in 22 clinical trials involving 226 patients who had amenorrhea/galactorrhea associated with hyperprolactinemia and no demonstrable pituitary tumor. Of the 187 patients evaluated for efficacy, 80% experienced reinitiation of menses (or pregnancy without first having menses); the average treatment time (excluding those who conceived) was 5.7 weeks. Galactorrhea was significantly (at least 75%) reduced in 76% of the 187 patients after an average treatment tome of 6.4 weeks, and was completely suppressed in 58% after 12.7 weeks. Maximum reduction in serum prolactin levels occurred within the first 4 weeks of therapy and the reduced levels were maintained during treatment; moreover, there was a strong correlation between prolactin reduction and clinical improvement. Adverse reactions were reported by 68% of the 226 patients evaluated for safety; in general, these reactions were mild and transient. Several patients experienced hypotension, but only 1 discontinued therapy because of it. Based on these findings, bromocriptine mesylate was judged safe and efficacious for this purpose.

Adolescent↗

Divorce and remarriage in a 65-year-old male following transphenoidal surgery and bromocriptine of hyperprolactinemic impotence: a dilemma.

Hyperprolactinemia, hypogonadotropinism, and subnormal plasma testosterone were found in a 65-year-old patient who had an enlarged sella turcica, complained of fatigue, and addmitted to decreased sexual interest and potency. Selective nontotal tumorectomy followed by bromocriptine therapy resulted in normoprolactinemia, increased plasma testosterone, and "rejuvenation difficult to follow" according to his wife. This patient described his sexual status as comparable to that of age 24 when he fathered his only child. Both wife and husband attributed the changes to bromocriptine and requested discontinuation (wife) and continuation (husband) of the treatment; because of the clinical indications, treatment was continued. Legally, a medical certification of a normal state of health was required before divorce--and subsequent marriage to a young woman--were permitted.

Bromocriptine↗

Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.

BACKGROUND: Several reports show evidence for the existence of high levels of prolactin (PRL) in alcoholic men and women. Previously we have shown that ethanol increases PRL release both in vivo and in vitro. How ethanol increases PRL release is not well understood. METHODS: In this study, we determined the effects of ethanol in the presence and absence of estradiol-17 beta on PRL messenger RNA (mRNA) levels, dopamine D2 receptor mRNA splicing, and the PRL-inhibitory response of a dopaminergic agent, bromocriptine, in the pituitary of Fischer-344 rats and in primary cultures of anterior pituitary cells. Real-time reverse transcriptase-polymerase chain reaction was used for mRNA detection, and radioimmunoassay was used for hormone detection. RESULTS: Estradiol and ethanol alone increased PRL mRNA expression in the pituitary gland. Ethanol also potentiated estradiol action on PRL mRNA expression in the pituitary. Determination of the D2 receptor splicing, by determining the changes in the percentage of D2 receptor mRNA expressed as its long form (D2L) and as its short form (D2S), revealed that both ethanol and estradiol altered D2 receptor splicing. Ethanol and estradiol, alone and together, increased the percentage of the D2L receptor but decreased the D2S receptor percentage. Similarly, ethanol and estradiol alone and in combination increased D2L, but decreased the D2S receptor percentage in primary cultures of pituitary cells. Evaluation of bromocriptine's inhibition of PRL release in primary cultures of pituitary cells indicated that ethanol reduced the ability of this D2 receptor agonist to inhibit PRL release. CONCLUSIONS: These results confirm estradiol's inhibition of D2 function and provide novel evidence that ethanol, like estradiol, reduces dopamine's ability to inhibit PRL release by modifying alternative splicing of the dopamine D2 receptor in the pituitary.

Alternative Splicing↗

Outcome of pregnancy in mothers given bromocriptine.

1 Information has been obtained on the outcome of 448 completed pregnancies in mothers who had been given bromocriptine at some stage in the early weeks of pregnancy. 2 The frequencies of spontaneous abortions, twin pregnancies and malformations have been compared with those reported for 'normal' populations. 3 Based on this limited material, we conclude that the use of bromocriptine to restore fertility in hyperprolactinaemic women is not associated with an increased risk of abortion, multiple pregnancy or the occurrence of malformations in the infants.

Abnormalities, Drug-Induced↗

Pituitary tumours during pregnancy in mothers treated with bromocriptine.

1 Out of 805 previously infertile women in whom pregnancy was achieved on bromocriptine treatment, 137 were diagnosed as having pituitary tumours. 2 In nine of these, tumour-related complications occurred during pregnancy, chiefly visual field impairment. Surgical intervention was considered necessary in two patients. In a third patient reinstitution of bromocriptine produced remission of symptoms. 3 Although the frequency of serious complications was low, the present state of knowledge indicates that surgery or irradiation of pituitary tumours should be preferred, at least as the first line of treatment, for patients contemplating pregnancy.

Adult↗